Effect of complement 3/5 knockout on renal proteomics landscape after ischemia and reperfusion injury in rats
Physiological Reports · 2026
DOI: 10.14814/phy2.71017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physiological Reports, 2026. Verfasst von Dinesh Bhattarai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Arkansas for Medical Science, Little Rock, Arkansas, USA. Hauptthemen laut MEDLINE: Reperfusion Injury, Complement C3, Kidney, Complement C5. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Department of Surgery, Division of Transplant Surgery, (Bhattarai), University of Utah School of Medicine, University of Arkansas for Medical Sciences (UAMS).
Abstract (Originalsprache)
Ischemia–reperfusion injury (IRI) is a major driver of acute kidney injury and development of chronic kidney disease. Although complement activation worsens IRI, the roles of upstream (C3) versus downstream (C5) components remain unclear. Renal IRI was surgically induced in C3 knockout (C3 − / − ) and C5 knockout (C5 − / − ) Lewis rats, and the renal function as well as histopathology were systematically assessed. Further, quantitative proteomics coupled with pathway enrichment analysis was performed to define complement‐dependent mechanisms. C3 and C5 deficiency conferred strong protection against renal IRI with improved renal function, reduced tubular necrosis, and lower expression of injury markers (KIM‐1, NGAL). Post‐IRI, C3 −/− enhanced mitochondrial, metabolic, and purine pathways while suppressing immune and extra‐cellular matrix programs. C5 −/− affected extracellular matrix remodeling and structural pathways with modest immune suppression. We demonstrate for the first time that upstream C3 −/− impacts a diverse range of renal injury and repair mechanisms compared to C5 −/− alone, although both interventions successfully reduced IRI‐mediated injury. Together, these findings highlight strategies for future complement‐based therapies targeting the upstream or downstream cascade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, University of Arkansas for Medical Science, Little Rock, Arkansas, USA.
- Division of Transplantation & Advanced Hepatobiliary Surgery, Department of Surgery, University of Utah, Salt Lake City, Utah, USA.
- Department of Medical Informatics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
- Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
- Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
ORCID-Profile: Dinesh Bhattarai, Amod Sharma, Madison McGraw, Nirmala Parajuli
Förderung
- NIDDK NIH HHS
- Department of Surgery, Division of Transplant Surgery, (Bhattarai), University of Utah School of Medicine
- University of Arkansas for Medical Sciences (UAMS)
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Bhattarai, D., Sharma, A., McGraw, M., Jun, S. R., Joshi, N., Gokden, N., Mackintosh, S., & Parajuli, N. (2026). Effect of complement 3/5 knockout on renal proteomics landscape after ischemia and reperfusion injury in rats. Physiological Reports. https://doi.org/10.14814/phy2.71017
Vancouver
Bhattarai D, Sharma A, McGraw M, Jun SR, Joshi N, Gokden N, et al. Effect of complement 3/5 knockout on renal proteomics landscape after ischemia and reperfusion injury in rats. Physiological Reports. 2026. doi:10.14814/phy2.71017
BibTeX
@article{Bhattarai2026,
author = {Bhattarai, Dinesh and Sharma, Amod and McGraw, Madison and Jun, Se-Ran and Joshi, Neelam and Gokden, Neriman and Mackintosh, Samuel and Parajuli, Nirmala},
title = {Effect of complement 3/5 knockout on renal proteomics landscape after ischemia and reperfusion injury in rats},
journal = {Physiological Reports},
year = {2026},
doi = {10.14814/phy2.71017}
}
EUVIMED